Baseline and dynamic plasma chromogranin A (CgA) level to predict clinical outcome and tumor response in Asian patients with gastroenteropancreatic neuroendocrine tumor (GEP-NET).

被引：0
|
作者：
Chou, Wen-Chi [1 ]
机构：
[1] Linkou Chang Gung Mem Hosp, Taoyuan, Taiwan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15151
引用
收藏
页数：1
相关论文
共 39 条
  • [31] A physiologically based pharmacokinetic model for [68Ga]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients
    Hinke Siebinga
    Berlinda J. de Wit-van der Veen
    Jos H. Beijnen
    Thomas P. C. Dorlo
    Alwin D. R. Huitema
    Jeroen J. M. A. Hendrikx
    EJNMMI Research, 13
  • [32] u Effect of lanreotide depot (LAN) on 5-hydroxyindoleacetic acid (5HIAA) and chromogranin A (CgA) in gastroenteropa ncreatic neuroendocrine (GEP NET) tumors: Correlation with tumor response and progression-free survival (PFS) from the phase III CLARINET study.
    Phan, Alexandria T.
    Wolin, Edward M.
    Liyanage, Nilani
    Mirakhur, Beloo
    Pitman, Susan W.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] Baseline tumor necrosis factor alpha levels predict the clinical response of infliximab therapy in patients with crohn's disease
    Nomura, Eiki
    Sato, Takeshi
    Kannno, Nana
    Sakuta, Kazuhiro
    Mizumoto, Naoko
    Shibuya, Rika
    Yagi, Makoto
    Iwano, Daisuke
    Sasaki, Yu
    Abe, Yasuhiko
    Nishise, Syoichi
    Ueno, Yoshiyuki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 : 131 - 131
  • [34] Extrahepatic 68Ga-DOTATATE-Avid Tumor Volume and serum Chromogranin A Predict Short-Term Outcome of 177Lu-DOTATATE in Late-Stage Metastatic Gastroenteropancreatic Neuroendocrine Tumors
    Song, Hong
    Kunz, Pamela
    Franc, Benjamin
    Moradi, Farshad
    Fisher, George
    Aparici, Carina Mari
    Iagaru, Andrei
    Davidzon, Guido
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [35] Extrahepatic 68Ga-DOTATATE-Avid Tumor Volume and Serum Chromogranin A Predict Short-Term Outcome of 177Lu-DOTATATE in Late-Stage Metastatic Gastroenteropancreatic Neuroendocrine Tumors
    Song, H.
    Kunz, P.
    Franc, B.
    Moradi, F.
    Fisher, G.
    Aparici, Mari C.
    Lagaru, A.
    Davidzon, G.
    NEUROENDOCRINOLOGY, 2020, 110 : 274 - 274
  • [36] The use of gallium-67 scintigraphy to monitor tumor response rates and predict long-term clinical outcome in patients with lymphoma
    Tuli, MM
    Al-Shemmari, SH
    Ameen, RM
    Al-Muhanadi, S
    Al-Huda, FA
    Ballani, N
    Khoshi, M
    Al-Enezi, F
    Bajciova, V
    Mottl, H
    CLINICAL LYMPHOMA, 2004, 5 (01): : 56 - 61
  • [37] Early, On-Treatment Levels and Dynamic Changes of Genomic Instability in Circulating Tumor DNA Predict Response to Treatment and Outcome in Metastatic Breast Cancer Patients
    Aguilar-Mahecha, Adriana
    Lafleur, Josiane
    Brousse, Susie
    Savichtcheva, Olga
    Holden, Kimberly A.
    Faulkner, Nathan
    McLennan, Graham
    Jensen, Taylor J.
    Basik, Mark
    CANCERS, 2021, 13 (06) : 1 - 12
  • [38] Dynamic Changes of Circulating Tumor DNA Predict Clinical Outcome in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
    Weber, Sabrina
    van der Leest, Paul
    Donker, Hylke C.
    Schlange, Thomas
    Timens, Wim
    Tamminga, Menno
    Hasenleithner, Samantha O.
    Graf, Ricarda
    Moser, Tina
    Spiegl, Benjamin
    Yaspo, Marie-Laure
    Terstappen, Leon W. M. M.
    Sidorenkov, Grigory
    Hiltermann, T. Jeroen. N.
    Speicher, Michael R.
    Schuuring, Ed
    Heitzer, Ellen
    Groen, Harry J. M.
    JCO PRECISION ONCOLOGY, 2021, 5 : 1540 - 1553
  • [39] Dynamic Changes of Circulating Tumor DNA Predict Clinical Outcome in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors (vol 5, pg 1540, 2021)
    Weber
    JCO PRECISION ONCOLOGY, 2022, 6
1234